Navigation Links
IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors

NEW YORK, Nov. 26, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that Michael Hershman has joined the IntelliCell Board of Directors. 

IntelliCell's Chairman and CEO, Dr. Steven Victor, stated, "Our Company is very pleased to announce today that Michael Hershman is joining our Board of Directors. His international experience and accomplishments will add a very significant capability to our Board and our Company. Mr. Hershman has long been recognized as one of the most influential business people worldwide and we are looking forward to working with him as we strengthen the IntelliCell executive management team with world class people."   

Said Mr. Hershman, "I am delighted to join the Board of IntelliCell and assist this cutting edge medical technology company which holds the potential to improve the well being of millions of people globally. I look forward to working with Dr. Victor and other Board members to develop IntelliCell as a leading company in Regenerative Medicine and contribute my efforts to creating an outstanding organization."

About IntelliCell BioSciences
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative, and preventative conditions of disease states with high unmet clinical needs. The Company has several patent pending applications including an industry unique method of obtaining autologous stromal vascular fraction cells (SVF) from the vasculature surrounding adipose tissue containing adult stem cells and a robust population of regenerative healing cells. The Company is also pioneering the development of autologous and allogeneic cells from living and non-living tissue donors for research purposes. IntelliCell is planning a series of in-human clinical studies with top tier universities for the treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics.  The Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into its ambulatory surgery center. 

About Michael Hershman
Michael Hershman is an internationally recognized expert on matters relating to transparency, accountability, governance, litigation and security.  Immediately prior to founding the Fairfax Group, Mr. Hershman served as deputy auditor general for the Foreign Assistance Program of the U.S. Agency for International Development (AID), where he led investigations and audits of major U.S. funded projects overseas, and was responsible for worldwide security at all foreign AID missions. Mr. Hershman was awarded the Superior Honor Medal for his service at AID.

In 1993, along with Peter Eigen, Mr. Hershman co-founded Transparency International, the largest independent, not-for-profit coalition promoting transparency and accountability in business and in government. For the past 6 years he has served Interpol as a member of the International Group of Experts on Corruption, and for the past 12 years, he has sat on the board of the International Anti-Corruption Conference Committee.

Mr. Hershman is a member of the board of directors of the U.S. Chamber of Commerce Foundation, and advises the Chamber on corporate compliance issues. Since 2007, Mr. Hershman has been a member of the board of directors and the executive committee of the Center for International Private Enterprise.

For the past 12 years he has been a member of Interpol's International Group of Experts on Corruption and now serves as Vice Chairman. He is also on the board of the International Anti-Corruption Conference Committee. He also serves on the Financial Coalition against Child Pornography, a project of the National Center for Missing and Exploited Children. Additionally, he is a member of the Advisory Council of the George Mason University School of Information Technology and Engineering.

Since 2008, he has been named every consecutive year to the Ethisphere Institute's list of the top 100 most influential people in business ethics worldwide.

Michael Hershman has given hundreds of speeches throughout the world on issues related to transparency and accountability and has provided commentary on ABC, CBS, NBC, PBS, CNN, CNBC, MSNBC and the Fox News Channel as well as countless national radio shows. For five years he was the co-host of the Public Radio Law Show. He has been quoted and published in the Wall Street Journal, the New York Times, the New York Post, the Washington Post, USA Today, the Financial Times, the National Law Journal and other print media.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.


IntelliCell BioSciences, Inc.
Robert J. Sexauer
Email Contact:  
(646) 576-8706  

SOURCE IntelliCell BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
2. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
3. IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
4. IntelliCell BioSciences Expands Management Team
5. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
6. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
7. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
8. Amarantus BioSciences Wins MANF Patent Challenge in Europe
9. Amarantus BioSciences Issues CEO Letter to Shareholders
10. Amarantus BioSciences Secures $1.1 Million in Financing
11. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
Post Your Comments:
(Date:11/27/2015)... Pittsburgh, PA (PRWEB) , ... November 27, 2015 ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, ... analytical chemistry and applied spectroscopy, covers a wide range of applications such as, ...
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 27th Annual ... . .   Listeners ... prior to the presentation to download or install any ... available on the website approximately one hour after the ...
Breaking Biology Technology:
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
Breaking Biology News(10 mins):